Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
Neurocrine released survey data showing significant employment impacts of tardive dyskinesia (TD), with 1 in 5 working adults quitting jobs due to symptoms and respondents missing 8 hours of work/school weekly prior to treatment. The findings, released during Tardive Dyskinesia Awareness Week, support the use of FDA-approved VMAT2 inhibitors like INGREZZA to reduce this burden.
Key figures
- Survey respondents td
- 70
- Survey respondents total
- 100
- Patients quitting job pct
- 20%
- Survey respondents caregivers
- 30
- Patients missed work hours week
- 8
- Survey respondents employment criteria
- 59
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.